

RESEARCH

Open Access



Expression of COX-1, COX-2, 5-LOX and CysLT₂ in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease

Monique Vorsprach^{1*}, Christoph Arens², Stephan Knipping³, Dörte Jechorek⁴, Sabine Stegemann-Koniszewski¹, Eva Lücke¹ and Jens Schreiber¹

Abstract

Background: Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD. It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance.

Objective: We sought to analyze differences in the expression of cyclooxygenases type 1 and 2 (COX-1, COX-2), arachidonate 5-lipoxygenase (5-LOX) and cysteinyl leukotriene receptor type 2 (CysLT₂) in nasal polyps and the bronchial mucosa of patients with aspirin intolerant asthma (AIA, $n = 23$) as compared to patients with aspirin tolerant asthma (ATA, $n = 17$) and a control group with nasal polyps, but without asthma (NPwA, $n = 15$).

Methods: Tissue biopsies from nasal polyps and bronchial mucosa were obtained during surgical treatment of nasal polyps by endonasal functional endoscopic sinus surgery (FESS) under general anesthesia from intubated patients. Immunohistochemistry was used to analyze the expression of COX-1, COX-2, 5-LOX and CysLT₂ in nasal and bronchial mucosa. Categorization into the different patient groups was performed according to the patient history, clinical and laboratory data, pulmonary function and provocation tests, as well as allergy testing.

Results: We observed a stronger expression of 5-LOX and CysLT₂ in submucosal glands of nasal and bronchial tissue compared to epithelial expression. The expression of COX-1 and COX-2 was stronger in epithelia compared to submucosal glands. There was a similar expression of the enzymes and CysLT₂ between upper and lower airways in all patient groups. We did not detect any significant differences between the patient groups.

Conclusions: The AA-metabolizing enzymes and the CysLT₂ were expressed in a very similar way in different microscopic structures in samples of the upper and lower airways of individual patients. We did not detect differences between the patient groups indicating the pathogenetic role of AA metabolism in these disorders is independent of the presence of NSAR-intolerance.

*Correspondence: monique.vorsprach@med.ovgu.de

¹ Department of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany

Full list of author information is available at the end of the article



Keywords: Asthma, Nasal polyps, Aspirin exacerbated respiratory disease, Arachidonic acid, Cyclooxygenases, Lipoxygenases, Leukotrienes

Background

Aspirin exacerbated respiratory disease (AERD; formerly “aspirin-induced asthma”) is a frequent disorder. A study published in 2014 points out, that there is a prevalence of 7% of AERD within asthma patients. Among patients with severe asthma it can even reach 14%. Furthermore, patients with chronic sinusitis with nasal polyps (CRSwNP) show a prevalence between 9 and 10% of AERD [1]. Performing aspirin provocation tests, it has been shown, that AERD is an underdiagnosed disorder [2]. AERD is usually characterized by upper and lower airway involvement. CRSwNP as well as bronchial asthma are hallmarks of this disorder. Typically, asthma deteriorates after exposure to aspirin or other nonsteroidal anti-inflammatory drugs (NSAID). Frequently asthma in AERD is nonatopic, severe and difficult to treat. Upper airway involvement has a significant impact on patients’ quality of life. The nasal condition is named chronic hyperplastic eosinophilic sinusitis (CHES) [3] and resembles bronchial asthma immunologically. Both in upper and lower airways Th-2 like immune responses are crucial, involving the cytokines IL-3, IL-4, IL-5, IL-13, eotaxin and GM-CSF [4–6] as well as activated eosinophils [7]. Nevertheless, only a part of patients with Th-2-mediated asthma suffer from intolerance to NSAID. These substances inhibit cyclooxygenase type 1 (COX-1), an enzyme which metabolizes arachidonic acid (AA) towards prostaglandins (PGs) and thromboxanes (TXs) [8, 9]. Following hydrolysis from the phospholipid layer, the AA metabolism follows two major pathways. On the one hand side leukotrienes (LTs) are being produced by 5-LOX and on the other hand side PGs and TXs through the COX pathway. There are two isotypes of the COX enzyme. While COX-1 is a ubiquitously occurring enzyme, COX-2 expression occurs after cytokine stimulation in inflamed tissue only [10]. The cysteinyl leukotrienes (Cys-LTs) are metabolites produced through the 5-LOX pathway leading to bronchoconstriction, vasodilatation, mucus production and recruitment of neutrophils and eosinophils in the lung through the corresponding receptors type 1 and 2 (CysLT₂) [10–14]. All these phenomena are hallmarks of severe asthma. It is assumed, that in AERD there is an imbalance in the metabolism of AA. Inhibition of COX-1 results in a reduction of PGs and a consecutive shift towards the LOX-pathway with increased production of LTs (LTC₄, LTD₄, LTE₄) which are regarded to play a pivotal role in

the pathogenesis of asthma [10]. Furthermore, a role of prostaglandin E₂ (PGE₂) in upper and lower respiratory tract involvement in AERD is assumed [15]. PGE₂ is a pleiotropic metabolite harboring anti-inflammatory, anti-fibrotic and immunorestrictive potential, that can at the same time also mediate proinflammatory responses [15–17].

Although there is good evidence for a pathogenetic role of AA-metabolism in respiratory diseases [10, 18], it is still unknown whether the relevant enzymes are expressed similarly in upper and lower airways. To the best of our knowledge, no studies have been reported in which AA-metabolizing enzymes were analyzed comparatively in nasal polyps and bronchial mucosa of the same subjects. Therefore, with regard to the “one airway, one disease” concept [19], we analyzed the immunoreactivity of COX-1, COX-2, 5-LOX and CysLT₂ in both nasal polyps and bronchial mucosa specimens from patients with aspirin intolerant asthma (AIA) in comparison to aspirin tolerant asthma patients (ATA) and controls with nasal polyps, but without asthma (NPwA).

Methods

Subjects and study design

We included patients, which were admitted for nasal polyposis surgery. These patients were divided into three groups depending on the presence of asthma with or without NSAID intolerance. Asthma was defined according to current guidelines based on the results of medical history with a standardized questionnaire (Asthma Control Test; ACT) [20] and pulmonary function tests including inhalative methacholine provocation tests. Standard skin prick testing defined atopy. Aspirin sensitivity was identified by inhalative aspirin provocation challenge in patients suffering from asthma. Patients of the control group suffered from CRSwNP with indication for surgery without a diagnosis of asthma. The study was approved by the Ethics Committee of the Faculty of Medicine of the Otto-von-Guericke-University Magdeburg and all patients gave written informed consent.

Sample collection

Endonasal functional endoscopic sinus surgery (FESS) was performed in intubated and ventilated patients. Resected nasal polyps were preserved for further analysis. Fiberoptic bronchoscopy was performed via

the endotracheal tube and 3–4 biopsies of the bronchial mucosa were obtained from the right main bronchus. The samples were preserved in 4% formalin until analysis. Automated dehydration was performed with ethylic alcohol (3 × 100%, 2 × 96% and 1 × 75%) and xylol, followed by embedding in paraffin. The specimens were cut into 3 μm slices by a microtome (RM 2155, Leica Instruments GmbH, Nussloch, Germany) and standardized hematoxylin and eosin (H&E)-staining was performed for overview staining.

Immunohistochemistry and image analysis

The immunohistochemical detection of 5-LOX, COX-1, COX-2 and CysLT₂ was performed on paraffin slices. After dehydration, dewaxing and doubled hydration of the slices, further procedures were performed, using standard automatised conditions in a BENCHMARK[®] ULTRA Immunostainer (Ventana, Tucson, USA). After antigen demasking of the slices and blocking of endogenous biotin (iVIEW[®]-BLOCKER, Ventana), incubation with the primary and secondary antibody was performed. We used specific antibodies against 5-LOX (1:50; Abcam, Cambridge, UK), COX-1, COX-2 (both 1:50; Cayman Chemical, Ann Arbor, USA) and CysLT₂ (1:100; Abcam, Cambridge, UK) as previously described [21–23]. The color reaction was performed using iVIEW diamino-benzidine (iVIEW[®]-DAB) and the color enhancer iVIEW[®]-COPPER (both Ventana). Subsequently, hematoxylin staining was carried out. Before covering the slices with Canada-balm, dehydration using alcohol and xylol was performed. As a positive control, stomach mucosa was used. As a negative control the primary antibody was substituted by mouse or rabbit IgG antibodies (ab27479/ab27478, Abcam, Cambridge, UK). For the semiquantitative evaluation of the immunohistochemical reaction towards 5-LOX, CysLT₂, COX-1 and COX-2, light microscopy in 100-times to 400-times resolution (Eclipse E200, Nikon, Japan) was performed. The analysis of the cytoplasmic expression in epithelial cells of nasal and bronchial tissue was performed separately for the respiratory epithelium, the squamous epithelium and the local submucosal glands. In order to evaluate immunoreactivity, we used the immunoreactive score (IRS) of Remmele et al. [24, 25]. We focused on staining intensity (SI) and the frequency of immunopositive cells (percent positive; PP). The scale for SI included values from 0 to 3, whereas 0 implied no, 1 a low, 2 a moderate and 3 a strong staining. The scale for PP ranged from 1 to 10 in which the percentage of immunopositive cells out of the total epithelial cells was determined in 10% steps, e.g. 5 = 50% of the cells were immunopositive. In each specimen SI and PP was evaluated for 3 representative regions of each kind of

epithelial layer to determine a mean value. From these values the immunoreactive score (IRS = SI × PP) was calculated. The preparations were fully examined. If one type of epithelium or mucosal glands were not detected, this was noted as a missing value in the statistical data collection.

Statistical analysis

Data analysis was conducted using the software SPSS[®] (Statistical Packages for Social Sciences, Version 25 for Microsoft Windows[®]). For the statistical analysis of two groups a standard t-test for independent variables was performed. In this study we focused mainly on the comparison of three groups, for which ANOVA (analysis of variances) was performed by post hoc analysis (multiple testing, Tukey). $P < 0.05$ indicated statistically significant differences. In order to compare between the different tissue types within subjects, we used a mixed linear model. We determined the patient group characteristics and the tissue type as factors for the mixed model. Paired tissue comparisons were performed by Bonferroni correction.

Results

Clinical data and laboratory parameters

Clinical and demographic details as well as laboratory parameters of the study subjects are shown in Table 1.

AIA patients showed increased counts of eosinophilic granulocytes with a statistically significant difference between AIA and NPwA ($p = 0.001$) and between ATA as compared to NPwA patients ($p = 0.009$), respectively (Table 1). Atopy, based on skin prick test results, was present in 34% of AIA and 47% of ATA, but none of the NPwA patients. The differences between the two groups of asthmatics did not reach statistical significance (Table 1).

Histology of nasal polyps and bronchial tissue

In nasal specimens from ethmoidal, maxillary, frontal and sphenoid sinuses respiratory mucosa with goblet cells was detected histologically. Some samples showed subepithelial infiltrations with lymphocytes, plasma cells and eosinophils. The mucosa frequently showed an edematous appearance in all groups. Bronchial biopsies ranged from 0.2 to 0.6 cm in size. We detected bronchial ciliated epithelium with occasional goblet cells in all specimens. Some samples showed squamous epithelial metaplasia. We observed an extensive inflammatory infiltration in some samples, in others only a few lymphocytes. We also observed local mucosal glands and bronchial smooth muscle cells. These observations were not specific for particular patient groups. Infiltrations of eosinophilic granulocytes were found in nasal polyp

Table 1 Clinical data and laboratory parameters of the study subjects

Group	AIA (n = 23)	ATA (n = 17)	NPwA (n = 15)
Male/female (n)	11/12	12/4	11/4
Age in years, mean (range)	48.7 (18–70)	51.2 (40–67)	43.2 (19–68)
Asthmatic patients, n	23	17	0
Atopic patients, n (%)	8 (34%)	8 (47%)	0
Number of previous FESS operations; mean (range)	2 (1–8)	1.4 (1–6)	1.38 (1–2)
Absolute eosinophilic blood counts (Gpt/l); mean (range)	0.486 (0.134–0.872)	0.263 (0.079–0.458)	0.116 (0.1–0.15)
Eosinophilic infiltrations in nasal polyps, n (%)	18 (78.3%)	14 (82.3%)	11 (73.3%)
Eosinophilic infiltrations in bronchial mucosa, n (%)	5 (21.7%)	3 (17.6%)	1 (6.6%)

The table shows the parameters as means and range

samples of all groups. In bronchial tissue we in general detected less eosinophilic infiltrations, most likely due to the small size of the biopsy samples (Table 1).

Expression of 5-LOX

Nasal immunoreactivity for 5-LOX did not show significant differences between groups (Fig. 1a–c). The highest expression of 5-LOX was observed in submucosal glands, with a statistically significant difference between " glands ($p = 0.038$), (Table 2, Fig. 4a). Similar observations were made comparing submucosal glands with squamous epithelium, these differences however did not reach statistical significance ($p = 0.094$) (Table 2). In bronchial tissue, we observed a medium 5-LOX expression in submucosal glands and a low expression in the bronchial epithelial layers (Fig. 1d–f) with a highly significant difference between glands and epithelium (each $p < 0.001$) (Table 2). Comparing patient groups, we detected a stronger expression of 5-LOX in the respiratory epithelial layer of controls as compared to asthmatic patients, however not reaching statistical significance (Fig. 1d).

Expression of COX-1

The expression of COX-1 in polypoid nasal tissue showed no statistically significant differences between the patient groups. We detected a medium COX-1 expression in all investigated epithelial layers and submucosal glands (Figs. 2a–c, 4b). As for 5-LOX, also the analysis of COX-1 expression revealed a significant difference between

submucosal glands and the respiratory ($p = 0.001$) as well as the squamous epithelium ($p = 0.003$), with the lowest IRS in submucosal glands (Table 2). While medium COX-1 immunoreactivity was detected in the bronchial tissue of asthmatic patients in the submucosal glands and epithelia, there was no COX-1 expression in the submucosal glands of controls (Fig. 2d–f). Furthermore, we observed a significant difference between low bronchial COX-1 expression in submucosal glands and a stronger IRS in the respiratory ($p = 0.0028$) and squamous epithelium ($p = 0.003$), respectively, with the highest expression in the squamous epithelium (Table 2).

Expression of COX-2

Analyzing the expression of the inducible COX-2 in nasal polyp tissue, we observed strong immunoreactivity within the epithelial layers with IRS values up to the maximum score of 30 (Figs. 3a–c, 4c). Again, we detected highly significant differences between submucosal glands and each type of epithelium ($p < 0.001$) (Table 2). As for COX-1, COX-2 expression was lowest in the submucosal glands as compared to the respiratory as well as squamous epithelium. However, we did not detect any remarkable patient group differences (Fig. 3a–c). Regarding bronchial COX-2 expression, we observed a significantly increased mean expression in epithelia (respiratory: $p = 0.002$ and squamous: $p = 0.011$) as compared to submucosal glands without any patient group differences (Fig. 3d–f).

(See figure on next page.)

Fig. 1 5-LOX immunoreactivity (IRS). Results of the staining of nasal (a–c) and bronchial (d–f) samples for 5-LOX are shown as boxplot diagrams. The lower and upper boundaries indicate the 25% and 75% quartile, respectively. Minimum and maximum values are indicated as whiskers and the dot represents the group median. Outliers were plotted as individual points. **a** Nasal respiratory epithelium (AIA: $n = 22$, ATA: $n = 16$, NPwA: $n = 15$), **b** nasal submucosal glands (AIA: $n = 22$, ATA: $n = 16$, NPwA: $n = 14$) and **c** nasal squamous epithelium (AIA: $n = 18$, ATA: $n = 12$, NPwA: $n = 12$), without significant differences in patient group comparisons. **d** Bronchial respiratory epithelium (AIA: $n = 15$, ATA: $n = 14$, NPwA: $n = 8$), **e** bronchial submucosal glands (AIA: $n = 11$, ATA: $n = 9$, NPwA: $n = 6$) and **f** bronchial squamous epithelium (AIA: $n = 10$, ATA: $n = 12$, NPwA: $n = 5$), without significant differences in patient group comparison




Table 2 Comparison of the expression of 5-LOX, COX-1, COX-2 and CysLT₂ between the respiratory epithelium, the submucosal glands and the squamous epithelium

	RE; mean (SE)	SG mean (SE)	SEP mean (SE)	<i>p</i> -value RE vs. SG	<i>p</i> -value SEP vs. SG	<i>p</i> -value RE vs. SEP
5-LOX nasal polyps	9.645 (1.197)	13.588 (1.241)	9.42 (1.59)	0.038	0.094	NS
5-LOX bronchial tissue	7.266 (1.458)	15.901 (1.778)	6.915 (1.516)	0.001	0.001	NS
COX-1 nasal polyps	13.287 (1.82)	10.24 (1.42)	13.784 (1.774)	0.001	0.003	NS
COX-1 bronchial tissue	10.611 (1.912)	5.103 (1.959)	11.83 (2.077)	0.028	0.003	NS
COX-2- nasal polyps	21.245 (1.335)	13.763 (0.978)	20.959 (1.494)	< 0.001	< 0.001	NS
COX-2 bronchial tissue	14.47 (1.898)	7.406 (1.581)	13.794 (1.947)	0.002	0.011	NS
CysLT ₂ nasal polyps	3.041 (0.895)	18.851 (1.125)	3.078 (0.895)	< 0.001	< 0.001	NS
CysLT ₂ bronchial tissue	1.938 (0.851)	13.969 (1.841)	1.936 (0.581)	< 0.001	< 0.001	NS

General comparison of the mean immunoreactive score (IRS) of the respiratory epithelium (RE), submucosal glands (SG) and squamous epithelium (SEP), irrespective of the patients' groups, using the mixed linear statistical model. Mean IRS are indicated +/- standard error (SE). NS nonsignificant

Expression of CysLT₂

Analyzing CysLT₂ immunoreactivity in nasal tissue, we detected a medium expression in submucosal glands that was clearly and significantly reduced in the epithelia (each $p < 0.001$) (Table 2, Fig. 4d). “ between the patient groups (Fig. 5a–c). In the respiratory epithelium of bronchial tissue, we detected CysLT₂ expression only in a few subjects, in the squamous epithelium only in one subject (Fig. 5c–f). Epithelial cells mainly showed immunoreactivity in the apical part of the goblet cells. A medium expression was found in the analyzed submucosal glands and comparing means, we detected highly significant differences between submucosal glands and the epithelia (each $p < 0.001$) (Table 2).

Discussion

In this study we analyzed the expression of COX-1, COX-2, 5-LOX and CysLT₂ in both nasal polyps and bronchial mucosa from patients with AIA in comparison to ATA patients and non-asthmatic controls with nasal polyps (NPwA). In contrast to other studies, we focused on analyzing immunoreactivity in both nasal and bronchial tissue of the same subjects.


Clinically, we detected 34 % atopic patients within the AIA group by standard skin-prick testing. This is in contrast to the common assumption that AIA patients are mostly nonatopic asthmatics [26]. At the

same time, this finding is well in line with the AIANE study by Szczeklik et al. [2] where likewise 34 % of AIA patients revealed atopy by skin-prick test. In our study blood counts of eosinophils were significantly increased between AIA and ATA and controls ($p = 0.001$), as well as between ATA and controls ($p = 0.001$), respectively. This is in accordance with several published observations, indicating an important pathogenetic role of these cells. Thus, Yamaguchi et al. [27] analyzed blood and nasal sinus eosinophil counts in 30 ATA und AIA patients. While the eosinophilic count in ATA sinuses did not differ as compared to controls, AIA patients showed significantly increased ($p < 0.05$) eosinophilic concentrations in ethmoidal cells. Furthermore, a positive correlation was found between blood and nasal sinus eosinophil counts and concentrations in ethmoidal cells ($r = 0.5249$; $p < 0.0001$). Therefore, our data regarding significantly increased blood eosinophil counts in AIA are in line with these previous reports, but this cell population does not discriminate between AIA and ATA patients.

Regarding the expression of LOX-5, we observed a stronger 5-LOX expression in submucosal glands of nasal polyps and bronchial tissue as compared to the epithelial layers. Overall, we detected medium 5-LOX expression without significant differences between the patient groups. In line with our results, Owens et al. [23] report

(See figure on next page.)

Fig. 2 COX-1 immunoreactivity (IRS). Results of the staining of nasal (a–c) and bronchial (d–f) samples for COX-1 are shown as boxplot diagrams. The lower and upper boundaries indicate the 25% and 75% quartile, respectively. Minimum and maximum values are indicated as whiskers and the dot represents the group median. Outliers were plotted as individual points. **a** Nasal respiratory epithelium (AIA: $n = 15$, ATA: $n = 12$, NPwA: $n = 15$), **b** nasal submucosal glands (AIA: $n = 12$, ATA: $n = 14$, NPwA: $n = 11$) and **c** nasal squamous epithelium (AIA: $n = 15$, ATA: $n = 13$, NPwA: $n = 6$), without significant differences in patient group comparisons. **d** Bronchial respiratory epithelium (AIA: $n = 13$, ATA: $n = 14$, NPwA: $n = 8$), **e** bronchial submucosal glands (AIA: $n = 5$, ATA: $n = 5$, NP: $n = 3$) and **f** bronchial squamous epithelium (AIA: $n = 11$, ATA: $n = 10$, NPwA: $n = 6$), without significant differences in patient group comparisons



(See figure on next page.)


Fig. 3 COX-2 immunoreactivity (IRS). Results of the staining of nasal (**a–c**) and bronchial (**d–f**) samples for COX-2 are shown as boxplot diagrams. The lower and upper boundaries indicate the 25% and 75% quartile, respectively. Minimum and maximum values are indicated as whiskers and the dot represents the group median. Outliers were plotted as individual points. **a** Nasal respiratory epithelium (AIA: $n = 23$, ATA: $n = 17$, NPwA: $n = 15$), **b** nasal submucosal glands (AIA: $n = 19$, ATA: $n = 16$, NP: $n = 15$) and **c** nasal squamous epithelium (AIA: $n = 13$, ATA: $n = 13$, NPwA: $n = 12$), without significant differences in patient group comparisons. **d** Bronchial respiratory epithelium (AIA: $n = 14$, ATA: $n = 13$, NPwA: $n = 8$), **e** bronchial submucosal glands (AIA: $n = 7$, ATA: $n = 8$, NPwA: $n = 5$) and **f** bronchial squamous epithelium (AIA: $n = 13$, ATA: $n = 11$, NPwA: $n = 7$), without significant differences in patient group comparisons

medium 5-LOX expression in submucosal glands in their immunohistochemical analysis, but with a significant difference between ATA and NP patients. Adamjee et al. [22] detected a three-fold increased 5-LOX expression in AIA as compared to ATA patients in their analysis of epithelial cells of nasal polyps. Altogether, currently the literature towards 5-LOX expression in the airways is rather limited and future studies will be needed to address these discrepancies and to clarify the role of 5-LOX expression in AIA.

Also, with regard to the nasal and bronchial expression of COX-1, we did not detect group differences. In the studies of Gosepath et al. [28] and Demoly et al. [29], a distinctive COX-1 expression in patients with nasal polyps and CRS was observed, also without significant differences [28, 29]. Cowburn et al. [30] detected similar results in bronchial tissue of AIA patients. Mullol et al. [31] found a lower COX-1 expression in nasal polyps of ATA patients without increase after cytokine exposure. In a study of Westergren et al. [32] in patients with allergic rhinitis, increased epithelial COX-1 expression was detected. This was also associated with increased numbers of intraepithelial mast cells. Owens et al. [23] analyzed the nasal expression of cyclooxygenases and lipoxygenases in AIA, ATA and control patients. They observed a rather increased epithelial expression of COX-1 in AIA und ATA patients as compared to controls. As in our study, the glandular COX-1 expression showed no patient group differences. Those reports suggest that the expression of COX-1 possibly plays a certain role in the formation of nasal polyps. However, the results of our study do not confirm this hypothesis and therefore suggest that the contribution of COX-1 expression to pathophysiology is only limited. Of note COX-1 is a constitutive expressed enzyme, possibly explaining the similar expression in all analyzed patients' groups.

Analyzing the expression of the inducible enzyme COX-2, we also did not observe significant patient group differences. Even though not statistically significant, the epithelial expression of COX-2 in nasal polyps of patients with AIA appeared lower as compared to ATA or NP patients (Fig. 3). Comparing the mean expression, we generally observed a lower COX-2 expression in submucosal glands with no patient group

difference (Table 2). Demoly et al. [29] also detected no differences of epithelial cyclooxygenase expression in patients suffering of CRS. In line with our results of slightly reduced COX-2 protein expression in nasal polyps of AIA patients, Pujols et al. [33] showed in a real-time PCR approach analyzing the dynamics of COX-2 expression in nasal tissue of AIA and ATA patients, that the baseline concentrations of COX-2 mRNA in nasal polyps were significantly reduced as compared to the nasal mucosa in both groups. While COX-2 mRNA expression in the nasal mucosa did not change after 1 h at room temperature, it increased significantly in ATA nasal polyps but not in AIA patients. Those results were related to the imbalanced arachidonic acid metabolism. In contrast, Yun et al. [34] detected COX-2 expression in submucosal glands, cytoplasm, mucosa, endothelial cells and vascular walls of nasal polyps. Owen et al. [23] detected an increased expression of COX-2 both in epithelial layers and submucosal glands, without group differences. In another study of Gosepath et al. [28], a lower COX-2 epithelial expression in nasal polyps versus CRS patients was found as compared to inflamed nasal mucosa. This possibly suggests, that COX-2 is an inducible enzyme in inflammatory tissue. In general, the available data on COX-2 expression are limited and as for 5-LOX and COX-1, further studies, also addressing enzyme activity, will be needed to comprehensively clarify their role for pathophysiology and as a marker in AIA. Interestingly, also patients in the NPwA group showed a relevant expression of the AA-metabolizing enzymes in the bronchial mucosa, even in the absence of clinical manifest asthma. This indicates that in these patients latent, clinically inapparent inflammatory reactions may occur in lower airways. We also did not detect significant group differences regarding the expression of the CysLT₂ receptor. CysLTs play an important role in the respiratory tract in the pathophysiology of AERD. An excessive cysteinyl-leukotriene production is characteristic for this disorder not only reflected by increased basal urine levels, but also after aspirin provocation [35–38]. In order to gain knowledge about the role of leukotriene in AERD, we did not analyze the enzyme expression of LTC₄ synthase, but the expression of the CysLT₂ receptor. In mammals there







Fig. 4 Representative sections of specimens immunostained for **a** 5-LOX (respiratory epithelium and submucosal glands of nasal polyp), **b** COX-1 (bronchial mucosa with squamous metaplasia), **c** COX-2 (respiratory epithelium of nasal polyp) and **d** CysLT₂ receptor (respiratory epithelium and submucosal glands of bronchial mucosa) from AIA patients. Brown staining represents protein expression. X 400

are two types of Cys-LT receptors, which function as a classical G-proteins [39]. The Cys-LT receptor type 1, which usually occurs in bronchial muscle cells, but also in macrophages and mast cells, has a higher affinity towards LTD₄ and the pharmaceutical leukotriene antagonists

montelukast, zafirlukast and pranlukast, which play an important role in standard asthma therapy [14]. We chose to analyze CysLT₂, because it binds equally to the bronchoconstrictors LTC₄ and LTD₄, but also with a higher affinity than the CysLT₁ receptor. In addition to



(See figure on previous page.)

Fig. 5 CysLT₂ immunoreactivity (IRS). Results of the staining of nasal (**a–c**) and bronchial (**d–f**) samples for CysLT₂ are shown as boxplot diagrams. The lower and upper boundaries indicate the 25% and 75% quartile, respectively. Minimum and maximum values are indicated as whiskers and the dot represents the group median. Outliers were plotted as individual points. **a** Nasal respiratory epithelium (AIA: *n* = 19, ATA: *n* = 14, NPwA: *n* = 14), **b** nasal submucosal glands (AIA: *n* = 15, ATA: *n* = 15, NPwA: *n* = 12) and **c** nasal squamous epithelium (AIA: *n* = 15, ATA: *n* = 14, NPwA: *n* = 14), without significant differences in patient group comparisons. **d** Bronchial respiratory epithelium (AIA: *n* = 13, ATA: *n* = 8, NPwA: *n* = 5), **e** bronchial submucosal glands (AIA: *n* = 7, ATA: *n* = 6, NPwA: *n* = 4) and **f** bronchial squamous epithelium (AIA: *n* = 5, ATA: *n* = 1, NPwA: *n* = 3), without significant differences in patient group comparisons

its expression in myeloid cells and smooth muscle tissue, CysLT₂ is also found in endothelial cells, cardiac Purkinje cells and in brain cells [12, 40]. In a study of Adamjee et al. [22], AIA patients showed four times more LTC₄ positive cells than ATA patients. Additionally, 5-LOX was expressed three times as strong in AIA than in ATA, without detecting any differences in the expression of COX-1 or COX-2. They also detected a five times increased blood eosinophilic count in AIA and a positive correlation between LTC₄ positive eosinophils and mucosal eosinophils [22]. Similar results were described by the same group in bronchial tissues of AIA, ATA and NP patients. Here, a five times higher expression of LTC₄ synthase in AIA was shown, as compared to ATA patients and 18 times higher towards controls [30]. Those results led to the assumption that a higher expression of LTC₄ synthase in AIA patients in mucosal eosinophils might be correlated to the occurrence of AERD in the upper and lower airways. Corrigan et al. [21] found a higher expression of CysLT₂ in submucosal glands of paranasal sinuses of ATA patients as compared to controls. The detection of similar CysLT₂ expression levels in the epithelium and submucosal glands within nasal and bronchial samples of AIA, ATA and NP patients in our study however suggests only a limited role for CysLT₂ expression in these cells in AERD.

Aspirin desensitization therapy and leukotriene receptor antagonists are treatment strategies, as they interfere with the arachidonic acid metabolism, although aspirin desensitization is more effective in most patients. Our results show similarities in arachidonic acid metabolism between nasal polyps and lower airways. This might be a pathophysiologic basis for the efficacy of the treatment in upper, as well as in lower airways.

Conclusion

The expression of the AA-metabolizing enzymes and the CysLT-receptor 2 was very similar in the upper and lower airways of individual patients, indicating a role of the AA pathway in both manifestations of these disorders. Therefore, these results support the “one airway, one disease” concept [19].

We detected, in both nasal and bronchial tissue, a stronger expression of 5-LOX and CysLT₂ in submucosal glands as compared to the epithelial expression indicating a relevance the LOX-pathway of AA-metabolism in these mucus producing structures. The nasal and bronchial epithelial expression of constitutive COX-1 and inducible COX-2 was stronger as compared to submucosal glands in both, indicating, that prostaglandin pathway of AA may play a more important role in epithelial cells. We did, however, not detect significant differences between the patient groups, which is in line with the assumption, that AA-metabolism is activated in a similar way in AIA and ATA with comparable disease severity. These enzyme expressions could be detected even in the lower airways of patients without bronchial asthma, indicating clinically inapparent changes. Our findings suggest that the postulated imbalance in AA metabolism possibly does not take place at the level of enzyme expression. This is partly a contradiction to the current literature. Comparing different studies, differences in mRNA abundance versus protein expression, which we analyzed in our study, need to be taken into account. Future studies, possibly applying multiple detection methods and larger patient groups will be needed to further increase our pathophysiological understanding of the alterations in AA metabolism in AERD and the key players in these.

Abbreviations

ACT: asthma control test; AERD: aspirin exacerbated respiratory disease; AIA: analgesic intolerant bronchial asthma; ATA: analgesic tolerant bronchial asthma; CHES: chronic hyperplastic eosinophilic sinusitis; CRSwNP: chronic sinusitis with nasal polyps; COX-1: cyclooxygenase 1; COX-2: cyclooxygenase 2; CRS: chronic rhinosinusitis; CysLTs: cysteinyl leukotrienes; **CysLT₂**: cysteinyl leukotriene receptor type 2; FESS: functional endoscopic sinus surgery; GM-CSF: granulocyte macrophage colony-stimulating factor; H[MYAMPE]: hematoxylin and eosin staining; IgG: immunoglobulin G; Il-3: interleukin 3; Il-4: interleukin 4; Il-5: interleukin 5; Il-13: interleukin 13; IRS: immune reactive score; 5-LOX: 5-lipoxygenase; **LTC₄**: cysteinyl leukotriene C₄; **LTC₄S**: cysteinyl leukotriene C₄ synthase; **LTD₄**: cysteinyl leukotriene D₄; **LTE₄**: cysteinyl leukotriene E₄; NPwA: nasal polyps without asthma; NSAID: nonsteroidal anti-inflammatory drug; PCR: polymerase chain reaction; PGs: prostaglandins; **PGE₂**: prostaglandin E₂; PP: count of immunopositively cells; SS: staining intensity; **Th₂**: type 2 T helper cell; TXs: thromboxans.

Acknowledgements

Not applicable.

Authors' contributions

MV performed the immunohistochemical examination of the specimen, analyzed and interpreted the patient data. CA and SK contributed in the patient recruiting process. JD assisted performing and interpreting the immunohistochemical examination. JS contributed in surveillance of the study and clinical background as well as writing the manuscript. SSK was a major contributor in writing the manuscript, analyzing the data and in helping presenting and interpreting the results. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved, with the issue of a positive ethical clearance with the reference number 25/10, by the University Hospital Magdeburg Ethics Committee before initiation. All patients gave written informed consent.

Consent for publication

There are no individual patient data. The data acquisition and analysis was performed anonymized.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Pneumology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany. ² Department of Otorhinolaryngology, Head- and Neck Surgery, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany. ³ Department of Otorhinolaryngology, Head- and Neck Surgery, Plastics Surgery, Dessau Medical Center, Martin-Luther-University Halle, Auenweg 38, 06847 Dessau, Germany. ⁴ Department of Pathology, University Hospital Magdeburg, Medical Faculty, Otto-von-Guericke-University, Leipziger Straße 44, 39120 Magdeburg, Germany.

Received: 22 August 2019 Accepted: 10 December 2019

Published online: 26 December 2019

References

- Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. *J Allergy Clin Immunol*. 2015;135(3):676–811. <https://doi.org/10.1016/j.jaci.2014.08.020>.
- Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European network on aspirin-induced asthma. *Eur Respir J*. 2000;16(3):432–6.
- Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. *Ann Allergy Asthma Immunol*. 2005;94(6):652–7. [https://doi.org/10.1016/S1081-1206\(10\)61323-3](https://doi.org/10.1016/S1081-1206(10)61323-3).
- Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in human nasal polyp tissue. *J Allergy Clin Immunol*. 1997;99(6 Pt 1):837–42.
- Minshall EM, Cameron L, Lavigne F, Leung DY, Hamilos D, Garcia-Zepeda EA, Rothenberg M, Luster AD, Hamid Q. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. *Am J Respir Cell Mol Biol*. 1997;17(6):683–90. <https://doi.org/10.1165/ajrcmb.17.6.2865>.
- Hamilos DL, Leung DY, Huston DP, Kamil A, Wood R, Hamid Q. GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). *Clin Exp Allergy*. 1998;28(9):1145–52.
- Weller PF. Human eosinophils. *J Allergy Clin Immunol*. 1997;100(3):283–7.
- Settipane RA, Stevenson DD. Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma. *J Allergy Clin Immunol*. 1989;84(1):26–33.
- Szczeklik A. Eicosanoids and aspirin-sensitive asthma. *Agents Actions Suppl*. 1987;21:195–202.
- Szczeklik A, Sanak M. The role of cox-1 and cox-2 in asthma pathogenesis and its significance in the use of selective inhibitors. *Clin Exp Allergy*. 2002;32(3):339–42. <https://doi.org/10.1046/j.1365-2222.2002.01333.x>.
- Dahlen B. Treatment of aspirin-intolerant asthma with antileukotrienes. *Am J Respir Crit Care Med*. 2000;161(2 Pt 2):137–41.
- Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. *Allergy Asthma Immunol Res*. 2014;6(4):288–95. <https://doi.org/10.4168/air.2014.6.4.288>.
- Laitinen LA, Laitinen A, Haahtela T, Vilkkla V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. *Lancet*. 1993;341(8851):989–90.
- Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz M, Figueroa DJ, Zeng Z, Connolly BM, Bai C, Austin CP, Chateaufneuf A, Stocco R, Greig GM, Kargman S, Hooks SB, Hosfield E, Williams DL, Ford-Hutchinson AW, Caskey CT, Evans JF. Characterization of the human cysteinyl leukotriene CysLT1 receptor. *Nature*. 1999;399(6738):789–93. <https://doi.org/10.1038/21658>.
- Machado-Carvalho L, Roca-Ferrer J, Picado C. Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity. *Respir Res*. 2014;15(1):100. <https://doi.org/10.1186/s12931-014-0100-7>.
- Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. *Physiol Rev*. 1999;79(4):1193–226. <https://doi.org/10.1152/physrev.1999.79.4.1193>.
- Vancheri C, Mastruzzo C, Sortino MA, Crimi N. The lung as a privileged site for the beneficial actions of PGE2. *Trends Immunol*. 2004;25(1):40–6.
- Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, Kiełbasa B. Aspirin intolerance and the cyclooxygenase-leukotriene pathways. *Curr Opin Pulm Med*. 2004;10(1):51–6.
- Giovannini-Chami L, Paquet A, Sanfiorenzo C, Pons N, Cazareth J, Magnone V, Lebrigand K, Chevalier B, Vallauri A, Julia V, Marquette C-H, Marcet B, Leroy S, Barbry P. The one airway, one disease concept in light of Th2 inflammation. *Eur Respir J*. 2018;52(4):1800437. <https://doi.org/10.1183/13993003.00437-2018>.
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol*. 2004;113(1):59–65. <https://doi.org/10.1016/j.jaci.2003.09.008>.
- Corrigan CJ, Mallett K, Ying S, Roberts D, Parikh A, Scadding G, Lee T. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. *J Allergy Clin Immunol*. 2005;115(2):316–22. <https://doi.org/10.1016/j.jaci.2004.10.051>.
- Adamjee J, Suh Y-J, Park H-S, Choi J-H, Penrose JF, Lam BK, Austen KF, Cazaly AM, Wilson SJ, Sampson AP. Expression of 5-lipoxygenase and cyclooxygenase pathway enzymes in nasal polyps of patients with aspirin-intolerant asthma. *J Pathol*. 2006;209(3):392–9. <https://doi.org/10.1002/path.1979>.
- Owens JM, Shroyer KR, Kingdom TT. Expression of cyclooxygenase and lipoxygenase enzymes in nasal polyps of aspirin-sensitive and aspirin-tolerant patients. *Arch Otolaryngol Head Neck Surg*. 2006;132(6):579–87. <https://doi.org/10.1001/archotol.132.6.579>.
- Weller W, Reif E, Ulmer WT. Long term inhalation studies on rats on the problem of silicosis prophylaxis with McIntyre aluminum powder. Histology, determination of oxyproline and dust content, examination of respiration and circulation. *Internationales Archiv für Arbeitsmedizin*. 1966;22(1):77–94.
- Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. *Der Pathologe*. 1987;8(3):138–40.
- Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. *Ann Intern Med*. 1968;68(5):975–83. <https://doi.org/10.7326/0003-4819-68-5-975>.
- Yamaguchi T, Ishii T, Yamamoto K, Higashi N, Taniguchi M, Okamoto M. Differences in urinary leukotriene E4 levels and distribution of eosinophils

- between chronic rhinosinusitis patients with aspirin-intolerant and -tolerant asthma. *Auris Nasus Larynx*. 2016;43(3):304–8. <https://doi.org/10.1016/j.anl.2015.09.016>.
28. Gosepath J, Brieger J, Mann WJ. New immunohistologic findings on the differential role of cyclooxygenase 1 and cyclooxygenase 2 in nasal polyposis. *Am J Rhinol*. 2005;19(2):111–6.
 29. Demoly P, Crampette L, Lebel B, Campbell AM, Mondain M, Bousquet J. Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa. *Clin Exp Allergy*. 1998;28(3):278–83.
 30. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, Lam BK, Penrose JF, Austen FK, Holgate ST, Sampson AP. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. *J Clin Invest*. 1998;101(4):834–46. <https://doi.org/10.1172/JCI620>.
 31. Mullol J, Fernández-Morata JC, Roca-Ferrer J, Pujols L, Xaubet A, Benitez P, Picado C. Cyclooxygenase 1 and cyclooxygenase 2 expression is abnormally regulated in human nasal polyps. *J Allergy Clin Immunol*. 2002;109(5):824–30.
 32. Westergren VS, Wilson SJ, Penrose JF, Howarth PH, Sampson AP. Nasal mucosal expression of the leukotriene and prostanoid pathways in seasonal and perennial allergic rhinitis. *Clin Exp Allergy*. 2009;39(6):820–8. <https://doi.org/10.1111/j.1365-2222.2009.03223.x>.
 33. Pujols L, Mullol J, Alobid I, Roca-Ferrer J, Xaubet A, Picado C. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. *J Allergy Clin Immunol*. 2004;114(4):814–9. <https://doi.org/10.1016/j.jaci.2004.07.050>.
 34. Yun C-B, Lee B-H, Jang T-J. Expression of glucocorticoid receptors and cyclooxygenase-2 in nasal polyps from nonallergic patients. *Ann Otol Rhinol Laryngol*. 2002;111(1):61–7. <https://doi.org/10.1177/000348940211100110>.
 35. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. *Am Rev Respir Dis*. 1988;137(4):847–54. <https://doi.org/10.1164/ajrccm/137.4.847>.
 36. Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. *Clin Exp Allergy*. 2002;32(10):1484–90.
 37. Kowalski ML, Sliwiska-Kowalska M, Igarashi Y, White MV, Wojciechowska B, Brayton P, Kaulbach H, Rozniecki J, Kaliner MA. Nasal secretions in response to acetylsalicylic acid. *J Allergy Clin Immunol*. 1993;91(2):580–98.
 38. Picado C, Ramis I, Rosellò J, Prat J, Bulbena O, Plaza V, Montserrat JM, Gelpí E. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. *Am Rev Respir Dis*. 1992;145(1):65–9. <https://doi.org/10.1164/ajrccm/145.1.65>.
 39. Lee TH, Austen KF, Corey EJ, Drazen JM. Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. *Proc Natl Acad Sci USA*. 1984;81(15):4922–5.
 40. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille JN, Abramovitz M, Cheng R, Williams DL, Zeng Z, Liu Q, Ma L, Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O'Neill GP, Metters KM, Lynch KR, Evans JF. Characterization of the human cysteinyl leukotriene 2 receptor. *J Biol Chem*. 2000;275(39):30531–6. <https://doi.org/10.1074/jbc.M003490200>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

